医学
内科学
转移性乳腺癌
临床终点
人口
癌症
乳腺癌
肿瘤科
AKT1型
外科
临床试验
蛋白激酶B
细胞凋亡
生物化学
化学
环境卫生
作者
Kevin Kalinsky,Fangxin Hong,Carolyn K. McCourt,Jasgit C. Sachdev,Edith P. Mitchell,James A. Zwiebel,L. Austin Doyle,Lisa M. McShane,Shuli Li,Robert J. Gray,Larry Rubinstein,David R. Patton,P. Mickey Williams,Stanley R. Hamilton,Barbara A. Conley,Peter J. O’Dwyer,Lyndsay N. Harris,Carlos L. Arteaga,Alice Chen,Keith T. Flaherty
出处
期刊：JAMA Oncology
[American Medical Association]
日期：2020-12-30
卷期号：7 (2): 271-271
被引量：69
标识
DOI：10.1001/jamaoncol.2020.6741
摘要
In the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial, agents targeting genetic tumor abnormalities are administered to patients. In the NCI-MATCH subprotocol EAY131-Y trial, patients with an AKT1 E17K-mutated metastatic tumor received the pan-AKT inhibitor capivasertib.
科研通智能强力驱动
Strongly Powered by AbleSci AI
bc
遇上就这样吧
dodo
YifanWang
核桃
back you up
斯寜
andrele
剑指东方是为谁
cdercder
MchemG
morena
樱桃猴子
科目三
ukz37752
iNk
mmyhn
田様
加菲丰丰
jyy
皖公网安备34019202002308
